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Abstract
Background: National and international primary CVD risk screening guidelines focus on using total CVD risk scores.
Recently, we developed a non-laboratory-based CVD risk score (inputs: age, sex, smoking, diabetes, systolic blood pressure,
treatment of hypertension, body-mass index), which can assess risk faster and at lower costs compared to laboratory-based
scores (inputs include cholesterol values). We aimed to assess the exchangeability of the non-laboratory-based risk score to
four commonly used laboratory-based scores (Framingham CVD [2008, 1991 versions], and Systematic COronary Risk
Evaluation [SCORE] for low and high risk settings) in an external validation population.
Methods and Findings: Analyses were based on individual-level, score-specific rankings of risk for adults in the Third
National Health and Nutrition Examination Survey (NHANES III) aged 25–74 years, without history of CVD or cancer
(n=5,999). Risk characterization agreement was based on overlap in dichotomous risk characterization (thresholds of 10-
year risk .10–20%) and Spearman rank correlation. Risk discrimination was assessed using receiver operator characteristic
curve analysis (10-year CVD death outcome). Risk characterization agreement ranged from 91.9–95.7% and 94.2–95.1% with
Spearman correlation ranges of 0.957–0.980 and 0.946–0.970 for men and women, respectively. In men, c-statistics for the
non-laboratory-based, Framingham (2008, 1991), and SCORE (high, low) functions were 0.782, 0.776, 0.781, 0.785, and 0.785,
with p-values for differences relative to the non-laboratory-based score of 0.44, 0.89, 0.68 and 0.65, respectively. In women,
the corresponding c-statistics were 0.809, 0.834, 0.821, 0.792, and 0.792, with corresponding p-values of 0.04, 0.34, 0.11 and
0.09, respectively.
Conclusions: Every score discriminated risk of CVD death well, and there was high agreement in risk characterization
between non-laboratory-based and laboratory-based risk scores, which suggests that the non-laboratory-based score can
be a useful proxy for Framingham or SCORE functions in resource-limited settings. Future external validation studies can
assess whether the sex-specific risk discrimination results hold in other populations.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death
globally, with 80% of these deaths occurring in middle and low
income countries.[1] Early detection and treatment of individuals
at risk is an important strategy for preventing or delaying primary
CVD events, thus reducing the health and economic burden of the
disease.[2,3] Most rigorous primary CVD screening guidelines
used in developed countries highlight the importance of using
absolute CVD or coronary heart disease (CHD) risk scores, such as
the Framingham or SCORE (Systematic COronary Risk
Evaluation) risk functions, which reflect the combined effects of
multiple risk factors on absolute CVD risk.[4]
One challenge of adopting this approach for developing coun-
tries is that they not have the cohort studies needed to create and
validate their own risk scores. Moreover, they do not have the
financial or physical capacity needed to carry out the wide-scale
laboratory testing required to implement established laboratory-
based risk scores. For example, in India, a cholesterol test that
costs $2–4 (U.S. dollars) would account for 5–10% of the 2005
estimate of per capita health spending ($40).[5] With these
limitations in mind, the World Health Organization (WHO) and
the International Society for Hypertension (ISH) developed
separate risk charts that include and exclude laboratory measures
(i.e., cholesterol values) for developing world regions. Specifically,
the non-laboratory-based charts only require age, sex, smoking
status, systolic blood pressure, and diabetes history to estimate
total CVD risk. However, the WHO/ISH charts have not yet
been validated, nor have they been compared to estab-
lished laboratory-based scores.[4,6] If non-laboratory-based risk
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compared to laboratory-based approaches, then individual
clinicians and national organizations can utilize simple risk scores
to serve the same screening function (i.e., identifying high-risk
individuals) in a more efficient manner.
Recently, we used the First National Health and Nutrition
Examination Survey (NHANES I) to develop a CVD risk score
that does not require laboratory inputs (i.e., total and/or HDL
cholesterol), which discriminated CVD events as accurately as a
total cholesterol-based score.[7] The appeal of a simple CVD risk
score is that results are available faster (i.e., all inputs can be
obtained within a 5–10 minute office visit) and at less cost relative
to risk assessment that requires laboratory testing. While non-
laboratory-based risk scores (developed in the NHANES I and
Framingham populations) have been shown to predict CVD
events well in the cohorts in which they were derived [7,8], less
attention has been given to how these scores compare to
laboratory-based scores in external validation populations. There-
fore, we sought to assess the exchangeability of the non-laboratory-
based score (derived from the NHANES I cohort) to commonly-
used laboratory-based scores as they would be used in clinical
practice in an external validation population. We conducted our
study using data from the Third National Health and Nutrition
Examination Survey (NHANES III) population, and found that
the non-laboratory-based score characterized and discriminated
CVD risk comparably to commonly-used laboratory-based scores.
Methods
Developing countries are at various stages of the epidemiologic
transition, in terms of both the distribution of CVD risk profiles
and the progress of implementing CVD prevention and treatment
efforts.[9] In order to account for this heterogeneity, we set to
compare the non-laboratory-based score to several laboratory-
based risks scores that were developed in distinct populations
during different time periods. We restricted our analysis to widely-
used laboratory-based scores that could be estimated using the
variables available in the NHANES III dataset (i.e., age, sex,
smoking, history of diabetes, blood pressure treatment, systolic
blood pressure, and total and HDL cholesterol). Therefore, we
evaluated two versions of Framingham (2008 and 1991 versions)
[8,10] and two versions of SCORE (for high and low risk settings)
[11] laboratory-based risk functions, using two methods: 1) We
evaluated how similarly the non-laboratory-based risk score
characterized individuals in the NHANES III for CVD risk
relative to each of the laboratory-based scores; 2) We used follow-
up cause-specific mortality data to assess the performance of each
risk score in discriminating 10-year CVD death in the NHANES
III population.
Appendix S1 describes the study populations that had been used
to develop each score, the inputs required for each score, and the
composite outcome that each score was designed to predict.
Among the laboratory-based risk scores, the composite outcome
that was used to construct the Framingham CVD risk equations
(myocardial infarction [MI], stroke, congestive heart failure
[CHF], CVD death, angina, peripheral vascular disease, coronary
insufficiency, and transient ischemic attack) is most similar to the
corresponding outcome for the non-laboratory-based risk score
(MI, stroke, CHF, CVD death, coronary bypass, percutaneous
transluminal coronary angioplasty). We therefore focused on the
comparison between the recently developed Framingham (2008)
CVD score and the non-laboratory score in our study, although
comparisons with the non-laboratory score were performed for all
four of the laboratory-based scores.
Although we assessed the performance in risk discrimination of
each score based on CVD death in the NHANES III population,
we did not alter any of the published coefficients of the scores, even
for those designed to predict fatal and non-fatal outcomes (the
Framingham and non-laboratory-based risk scores). This allowed
us to use the NHANES III follow-up data, which are limited to
cause-specific mortality (i.e., no data on non-fatal events), to
evaluate the risk scores as they would be used in practice (i.e.,
based on their published coefficients). It was not possible to assess
risk score calibration measures, which focus on predicted versus
observed events, for the Framingham and non-laboratory-based
scores due to the absence of non-fatal outcomes in the observed
events. The time interval for each risk prediction was not relevant
(i.e., 10-year or 5-year risk), since all of our analyses were based on
score-specific rankings of risk.
Study Population
The NHANES III is a complex, multi-stage, nationally
representative U.S. sample that contains health and nutrition
information for 33,394 persons aged 2 months and older.[12]
Baseline values were collected from 1988–1994, and cause-specific
mortality status is available for adults up to 2006, providing at least
10-year follow-up data for these individuals. Because the sampling
for each NHANES was conducted separately, none of the
individuals from the NHANES I population were intentionally
included in the NHANES III sample. The general methodology
and results for the NHANES III are described elsewhere.[13]
Among the 20,050 adults in the NHANES III population, 14,973
were between the ages of 25 and 74 years, and 1,742 of these
individuals were excluded for history of myocardial infarction,
heart failure, stroke or cancer, resulting in 13,248 individuals that
met our inclusion criteria. Among these individuals, 5,999 had
complete data required to calculate each risk score. Although we
focused our study on the population with complete data, we used
imputed data to address the possibility of missing values being a
confounder in our analysis.
The most common missing variable among individuals who
met the inclusion criteria was smoking (missing in 39% and 61%
of men and women, respectively), followed by total/HDL
cholesterol (missing in 9% and 7% of men and women,
respectively). Appendix S2 contains information about missing
data for each variable. The NHANES III data files contain five
multiple imputation datasets that fill missing data with plausible
values using independent draws from predictive distributions,
which were generated using multivariate regression methods. The
detailed methodology and performance of the NHANES III
multiple imputation procedures have been previously report-
ed.[14,15] Imputed datasets were complete for all variables
needed to calculate risk predictions for the five scores included in
this study, aside from missing values for history of diabetes for 17
individuals (6 men, 11 women). As a sensitivity analysis, we
combined results from multiple imputation datasets (with
adjustment for underestimated variance) using methods outlined
by Rubin (1987) for scalar (i.e., one-dimensional) estimates.[16]
Where possible, results were reported after adjustment for sample
weights to account for the complex sampling method used in the
NHANES III.[13]
Statistical analysis
The first step in our analysis was to calculate individual-level
risk predictions for each of the five scores included in the study.
Individuals were subsequently assigned ranks for each risk score by
sex. These ranks were used to assess agreement in dichotomous
risk characterization for the non-laboratory-based score compared
Non-Laboratory-Based vs. Laboratory-Based Scores
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Adult Treatment Panel (APT) III guidelines for treatment of high
cholesterol (10-year Framingham CHD risk .10%), individuals
were characterized as ‘‘high’’ or ‘‘low’’ risk for each score based on
their score-specific rank.[17] An alternative threshold of 10-year
CHD risk .20% was also assessed. Percent agreement between
the non-laboratory-based score and each of the laboratory-based
scores was calculated by adding the proportions of individuals that
were equivalently characterized as ‘‘high’’ or ‘‘low’’ risk by both
scores. Spearman rank correlation coefficients were computed for
the non-laboratory-based score compared to each of the
laboratory-based scores to assess the agreement in the rankings
across the full spectrum of risk thresholds. Pearson correlation
coefficients were not reported because risk score values were not
normally distributed.[18]
The performance in risk discrimination for each score was also
assessed using the individual score-specific ranks, with 10-year
CVD death as the outcome of interest. Causes of death for the
NHANES III population are verified by National Death Index
(NDI) death certificate match. CVD deaths were defined by
having an underlying cause of (International Classification of
Diseases [ICD]-10 codes in parentheses): Acute myocardial
infarction (I21-I22), other acute ischemic heart disease (I24),
atherosclerotic cardiovascular disease (I25.0), all other forms of
chronic ischemic heart disease (I20, I25.1–I25.9), or cerebrovas-
cular diseases (I60–I69). As a sensitivity analysis, 10-year total
death was also used as a follow-up outcome.
Receiver operator characteristic (ROC) curves were generated
for each score, and differences between the areas under each curve
(c-statistics) were assessed for the non-laboratory-based score
compared to each of the laboratory-based scores. The ROC curve
plots the true-positive rate (sensitivity) against the false-positive rate
(1-specificity), which graphically depicts the accuracy with which a
binary risk classification system (a risk score, in this study) correctly
predicts an outcome (10-year CVD death) across the full spectrum
of risk thresholds. The c-statistic, or area under the curve (AUC), is
a useful single-number summary that quantifies the discriminatory
power of the classification system, where values of 1.0 and 0.5
represent perfect and useless systems, respectively.[19] While c-
statistics were reported with and without adjustment for sample
weights, plots of ROC curves and significance tests for differences
in c-statistics were not adjusted for sample weights due to software
capability.
Un-weighted and weighted statistical analyses were performed
using SAS (Version 9) and SAS Survey Procedures, respectively,
and all significance testing was done at the 5% level.[20]
Results
Table 1 shows the risk profile characteristics of the NHANES
III study population by sex for the subpopulation for whom
complete data were available, with and without adjustment for
sample weights. Appendix S2 shows the same information for the
full population, which includes imputed values for missing data.
The average clinical characteristics for the imputed, weighted
populations skewed towards lower risk profiles compared to the
averages for populations with complete, unadjusted data. By
design, the weighted NHANES III population is representative of
the U.S. population.[21] The linked mortality data files contained
follow-up cause-specific death information for .99% of the
individuals that met the inclusion criteria. Vital status was known
for these individuals for up to 10 years after their baseline
interview date.
Based on a risk threshold that corresponds with a 10-year CHD
risk .10%, 42.2% of men and 18.8% of women in the study
sample (with complete data) would be characterized as ‘‘high’’ risk.
Figures 1a and 1b show the ranks for CVD risk as assessed by the
non-laboratory-based score plotted against the ranks for CVD
based on the Framingham (2008) CVD risk equation for men and
women, respectively. The figures show that 91.9% of men and
94.6% of women would be characterized as ‘‘high’’ or ‘‘low’’ risk
consistently using either risk score. Equivalently, 8.1% of men and
5.4% of women would be re-characterized as ‘‘high risk’’ by one
score to ‘‘low risk’’ by the other or vice versa. Table 2 shows the
percent agreement between the non-laboratory-based and all of
the laboratory-based scores using the same threshold. Agreement
was similar across genders, completeness of data, and adjustment
of sample weights. Percent agreement ranged from 91.9–95.7%
and 94.2–95.1% across the laboratory-based scores for men and
women, respectively. When a threshold of 10-year CHD risk
Table 1. Population characteristics of NHANES III population that met inclusion criteria.*
MEN (n=3,501) WOMEN (n=2,498)
Un-weighted Weighted** Un-weighted Weighted**
Age (years) 47.0 44.2 45.6 44.6
Currently smoker 53.8% 52.6% 59.4% 58.3%
History of diabetes 6.5% 4.3% 7.8% 5.5%
Blood pressure treatment 11.1% 8.8% 13.5% 10.0%
Systolic blood pressure (mmHg) 129.1 126.0 122.3 119.2
Total cholesterol (mg/dL) 205.1 204.0 206.5 204.4
HDL cholesterol (mg/dL) 47.4 45.5 54.6 54.4
Body-mass index (kg/m
2) 26.7 26.6 27.4 26.3
Race -- -- -- --
White (%) 66.1% 85.2% 64.5% 86.7%
Black (%) 30.5% 10.7% 33.2% 11.4%
Other or unknown (%) 3.4% 4.1% 2.3% 2.0%
*Incluion criteria: 25 yars#age#74 years and no history of myocardial infarction, stroke, heart failure, or cancer.
**Data adjusted for complex sampling method used in NHANES III to estimate nationally representative results.
doi:10.1371/journal.pone.0020416.t001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20416Figure 1. Agreement in risk characterization between Framingham (2008) CVD and non-laboratory-based risk scores. Rank variables
for the non-laboratory-based risk score are plotted against rank variables for the Framingham (2008) CVD score for adults aged 25–74 years with
complete data in the NHANES III population without history of MI, heart failure, stroke or cancer. Larger ranks indicate greater CVD risk. Size of
bubbles correspond to NHANES III sampling weights (i.e., larger bubbles indicate more individuals represented by sample weight). Based on a risk
threshold that corresponds to 10-year CHD risk (i.e., top 42.2% of men and 18.8% of women in the sample), 91.9% of men (Panel A) and 94.6% of
women (Panel B) would be similarly characterized as high or low risk by the non-laboratory-based and Framingham (2008) CVD risk scores.
doi:10.1371/journal.pone.0020416.g001
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in the study sample would be characterized as ‘‘high’’ risk,
respectively), the corresponding agreement ranges were 94.9–
96.5% and 96.6–97.9% for men and women, respectively.
Appendix S3 shows that these trends were consistent when the
full population (with imputed values) was analyzed.
Table 2 also shows the Spearman correlation coefficients for
each of the laboratory-based risk scores compared to the non-
laboratory risk score. The Spearman correlation results were
similar to the percent agreement findings in terms of trends across
scores and between imputed versus non-imputed datasets.
Specifically, the Spearman rank correlation coefficients ranged
from 0.957–0.980 and 0.946–0.970 across the laboratory-based
scores for men and women, respectively. All of the p-values for the
Spearman rank correlation coefficients were ,0.001, even after
adjusting the variance of imputed datasets. Appendix S3 shows
that the Spearman correlation results were consistent when the full
population (with imputed values) was analyzed.
From 10-year follow-up data for each individual (excluding
those with imputed risk characteristics values), there were 118 and
58 CVD deaths for men and women, which represented 26.6%
and 25.3% of the total deaths within the 10-year follow-up period,
respectively. Figures 2a and 2b show the ROC curves for the non-
laboratory-based risk score and the Framingham (2008) CVD risk
equation for men and women, respectively. For men (Figure 2a),
the c-statistics and 95% confidence intervals (CIs) for the non-
laboratory-based and Framingham (2008) CVD scores were 0.782
(0.739–0.825) and 0.776 (0.733–0.819), respectively. The corre-
sponding c-statistics and 95% CIs for women (Figure 2b) were
0.809 (0.751–0.866) and 0.834 (0.782–0.885), respectively. The
differences between the non-laboratory-based and the Framing-
ham (2008) CVD scores were not statistically significant for men,
but were for women (p-values of 0.44 and 0.04, respectively).
These results were similar after adjusting for sample weights (c-
statistics of 0.782 and 0.772 for the non-laboratory-based and
Framingham CVD risk scores in men, and 0.807 and 0.832 in
women, respectively). Appendix S4 shows that these trends were
consistent for the full population (with imputed values), for both
weighted and un-weighted analyses.
Table 3 and Appendix S4 also show the c-statistics with 95%
CIs for all scores by sex, completeness of data, and with and
without adjustment for sample weights. As seen in these tables, the
non-laboratory-based score did not have a statistically significantly
different c-statistics in any of the comparisons to the four
laboratory-based scores for men. In women, the non-laboratory-
based score had statistically significantly lower c-statistics com-
pared to the Framingham (2008) CVD risk function (in the
populations with and without imputed data), and statistically
higher c-statistics compared to the SCORE functions (for high and
low risk settings) in the full population that contained imputed data
(p-values of 0.02 and 0.01, respectively). Applying sample weights
resulted in very similar differences in c-statistics between the non-
laboratory-based and laboratory-based scores, relative to un-
weighted analyses. The non-laboratory-based score had higher c-
statistics compared to all laboratory-based scores in sensitivity
analyses using 10-year total death instead of 10-year CVD death
as the outcome of interest.
Discussion
In this study, we assessed the extent to which a non-laboratory-
based CVD risk score similarly ranked individuals and discrim-
inated risk of CVD death compared to four versions of laboratory-
based Framingham and SCORE equations. We observed strong
agreement in risk characterization between the non-laboratory-
based and laboratory-based scores, and that all scores performed
well in discriminating 10-year risk of CVD death in an external
validation cohort (the NHANES III population). Over 91% of
men and 94% of women were equivalently characterized as
‘‘high’’ or ‘‘low risk’’ by non-laboratory-based and laboratory-
based scores using a risk threshold based on current U.S.
guidelines (10-year CHD risk .10%).[17] This finding was robust
under a stricter risk threshold (10-year CHD risk .20%) and
across the full spectrum of risk. The results varied by sex for the
risk discrimination comparisons. In men, there were no statistical
differences in the prediction of 10-year CVD death for the non-
laboratory-based risk score compared to any of the laboratory-
based scores. In women, the recent Framingham (2008) CVD
score had statistically higher c-statistic (0.834) compared to the
non-laboratory-based score (0.809). All of the findings were
consistent when analyses were conducted with and without
imputed data and sample weights.
A potential problem of using any absolute CVD risk assessment
tool is that the population in which a given score was derived may
Table 2. Risk categorization results for four laboratory-based risk scores, each compared to non-laboratory-based risk score.
MEN (limited to those with complete data, n=3,501)
Score Un-weighted agreement* Weighted agreement* Spearman correlation**
Framingham CVD (2008) 92.2% 91.9% 0.957
Framingham CVD (1991) 92.5% 91.9% 0.961
SCORE high risk 95.6% 95.3% 0.979
SCORE low risk 95.8% 95.7% 0.980
WOMEN (limited to those with complete data, n=2,498)
Framingham CVD (2008) 93.4% 94.6% 0.946
Framingham CVD (1991) 92.8% 94.2% 0.946
SCORE high risk 94.3% 95.1% 0.970
SCORE low risk 94.4% 95.1% 0.970
*‘‘Agreement’’ based on dichotomous risk categorization corresponding to 10-year Framingham CHD risk .10%.
**All p-values for Spearman rank correlation coefficients ,0.0001.
**Spearman correlation results only available for un-weighted populations.
doi:10.1371/journal.pone.0020416.t002
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ultimately applied. Ideally, more cohort studies would be
conducted to develop setting-specific risk scores. However, since
many developing countries do not have the resources to conduct a
representative cohort study and develop their own scores, they
have little choice but to use scores that were derived from other
(more developed) settings as they have been doing for the last two
decades. Certainly, established risk scores from developed regions
may over- or underestimate risk in a given population. But if the
risk scores rank individuals similarly, a country could choose a risk
threshold to identify a certain percentage of its population that it
could afford to manage aggressively with medical therapy, while
offering life-style interventions for those at lower risk and
population-based strategies to reduce the risk in the overall
Figures 2. ROC curves (10-year CVD death outcome) for non-laboratory-based and Framingham (2008) CVD risk scores. Receiver
operator characteristic (ROC) curves for the non-laboratory-based (‘‘non-lab’’) and Framingham (2008) CVD (‘‘fram cvd’’) scores, with 10-year CVD
death as the outcome of interest, for individuals with complete data. For men (Panel A), the performances in risk discrimination, as assessed by the c-
statistic (i.e., area under the ROC curve) and 95% CI, were 0.782 (0.739–0.825) and 0.776 (0.733–0.819) for the non-laboratory-based and Framingham
(2008) CVD risk scores, respectively, with a p-value for the difference of 0.44. For women (Panel B), the c-statistics and 95% CI were 0.809 (0.751–0.866)
and 0.834 (0.782–0.885) for the non-laboratory-based and Framingham (2008) CVD risk scores, respectively, with a p-value for the difference of 0.04.
doi:10.1371/journal.pone.0020416.g002
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effectiveness studies that have shown that treatment decisions
based on the aggregate effects of multiple risk factors can result in
more efficient outcomes compared to treatment guidelines based
on single risk factors.[22,23,24] In our analysis, there was a high
level of agreement among the scores in stratifying individuals into
high and low risk categories, which suggests that a non-laboratory-
based risk score could reasonably serve the same screening
function as more expensive laboratory-based risk scores in
resource-poor settings.
The second objective of this study was to assess the risk
discrimination performance of each score in an external
validation population, which, to our knowledge, has not been
evaluated for non-laboratory-based CVD risk scores. We found
that all scores in analysis performed well, with c-statistics greater
than 0.77. A recent review of risk scores found that only 5 out of
17 external validations of the Framingham and SCORE
equations had c-statistics greater than 0.77.[4] Future studies
can examine if the sex-specific trends we found are observed in
other cohorts. If scores behave similarly in men, attention should
be given to the most convenient or least costly scores when
updating or creating primary CVD screening guidelines for
developing and developed countries. One example of how non-
laboratory-based risk scores could be incorporated was proposed
in a recent modeling study by Chamnam et al., where simple risk
assessment was included as the first stage of a stepwise screening
strategy.[25] The differences in risk discrimination between
scores in women could be due to differential biological effects
for specific risk factors, such as cholesterol (for the differences
between the non-laboratory-based and Framingham scores) or
diabetes and treatment for hypertension (for the differences
between the SCORE functions and all other scores), or these
findings could be due to statistical chance (p-value for difference
between recent Framingham CVD and non-laboratory-based
score=0.04). More research investigating these sex-specific
differences could further explain these findings.
A limitation of our analysis was that the follow-up data were
restricted to cause-specific mortality outcomes, which prevented
the calculation of risk score calibration measures. Although
calibration is an important component of risk score assessment,
scores are often recalibrated for different settings, a process that
does not alter the b-coefficients of the risk scores.[4,26] Therefore,
our findings would not be affected if scores are recalibrated, since
rankings of risk are only dependent on risk score b-coefficients.
However, as mentioned by Panagiotakos and Stavrinos, recali-
bration would require representative CVD incidence data, which
could be limited depending on the setting.[27]
In addition to the lack of calibration, our analysis did not
include the commonly-used ASSIGN-SCORE, PROCAM and
QRISK functions, as the social deprivation and family history
variables needed to calculate these functions were not available in
the NHANES III data.[28,29,30] The WHO/ISH risk charts
were not included because the underlying risk functions are not
publicly available.[6] Our main risk discrimination results were
also based on a relatively small number of events (176 CVD
deaths). Future external validation studies could be designed to
address these limitations.
In summary, we found that the non-laboratory-based and
laboratory-based scores evaluated in this study discriminated risk
of CVD death well in this external validation cohort. In men, the
non-laboratory-based score discriminated risk similarly to all of the
laboratory-based scores, which could have implications for
developing efficient, sex-specific primary CVD screening guide-
lines. Further investigation of the risk discrimination and
calibration performance of the non-laboratory-based score could
help confirm this finding. However, even if it assumed that
laboratory-based risk assessment is the gold standard, we found
that the non-laboratory-based risk score similarly characterized
high and low risk men and women compared to the Framingham
and SCORE functions. In resource-poor settings, non-laboratory-
based risk assessment could serve as a useful proxy for these more
intensive, expensive risk screening approaches.
Table 3. Risk discrimination results for four laboratory-based risk scores, each compared to non-laboratory-based risk score–CVD
death.
MEN (limited to those with complete data, n=3,501)
score
c-statistic (95% CI),
un-weighted p-value*
c-statistic,
weighted** sensitivity*** specificity*** PPV*** NPV***
Non-laboratory-based 0.782 (0.739, 0.825) -- 0.782 0.788 0.592 0.063 0.988
Framingham CVD (2008) 0.776 (0.733, 0.819) 0.44 0.772 0.788 0.591 0.063 0.988
Framingham CVD (1991) 0.781 (0.738, 0.823) 0.89 0.778 0.780 0.591 0.063 0.987
SCORE high risk 0.785 (0.743, 0.826) 0.68 0.784 0.805 0.592 0.065 0.989
SCORE low risk 0.785 (0.743, 0.826) 0.65 0.785 0.814 0.592 0.065 0.989
WOMEN (limited to those with complete data, n=2,498)
Non-laboratory-based 0.809 (0.751, 0.866) -- 0.807 0.638 0.823 0.079 0.990
Framingham CVD (2008) 0.834 (0.782, 0.885) 0.04 0.832 0.707 0.825 0.087 0.992
Framingham CVD (1991) 0.821 (0.766, 0.876) 0.34 0.821 0.700 0.824 0.085 0.991
SCORE high risk 0.792 (0.731, 0.854) 0.11 0.793 0.638 0.823 0.079 0.990
SCORE low risk 0.792 (0.730, 0.854) 0.09 0.792 0.655 0.823 0.081 0.990
*Difference in c-statistic compared to non-laboratory-based score, using un-weighted data.
*Italics indicate p-value ,0.05.
**Standard errors not available for weighted results.
***Using 10-year CHD risk .10% threshold, un-weighted data.
Abbreviations: Positive predictive value (PPV), negative predictive value (NPV).
doi:10.1371/journal.pone.0020416.t003
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